Activation of P53 in HepG2 cells as surrogate to detect mutagens and promutagens in vitro

被引：27

作者：

Boehme, Kathleen ^{[1
]}

Dietz, Yasmin ^{[1
]}

Hewitt, Philip ^{[1
]}

Mueller, Stefan O. ^{[1
,2
]}

机构：

[1] Merck KGaA, Merck Serono, Toxicol, D-64293 Darmstadt, Germany

[2] Karlsruhe Inst Technol, Inst Angew Biowissensch, Karlsruhe, Germany

来源：

TOXICOLOGY LETTERS | 2010年 / 198卷 / 02期

关键词：

P53; HepG2; Mutagens; Promutagens; Genotoxicity; Metabolic activation; GENE-TOX PROGRAM; DISCRIMINATE RODENT CARCINOGENS; DRUG-METABOLIZING-ENZYMES; PRIMARY HUMAN HEPATOCYTES; MOUSE BONE-MARROW; MICRONUCLEUS TEST; GENOTOXICITY TESTS; HUMAN-LIVER; HEPATOCELLULAR-CARCINOMA; METHYL METHANESULFONATE;

D O I：

10.1016/j.toxlet.2010.07.007

中图分类号：

R99 [毒物学（毒理学）];

学科分类号：

100405 ;

摘要：

The current genotoxicity tests of the standard in vitro battery, especially those using mammalian cells, are limited by their low specificity and highlight the importance of new in vitro tools. This study aimed to evaluate the suitability of HepG2 cells for assaying mutagens and promutagens. We determined P53 activity as surrogate genotoxicity endpoint in HepG2 cells. Our results revealed a significant P53-induction by actinomycin D, methyl methanesulfonate and etoposide. Prior to the investigation of promutagens we characterized HepG2 cells by analyzing the expression of 45 genes involved in xenobiotic metabolism and measuring the activity of selected Cytochrome-P450 (CYP) enzymes. We determined a limited metabolic capacity prompting us to employ a co-treatment with rat liver S9 as metabolic activation system (MAS) for promutagens. While cyclophosphamide showed an elevation of activated P53 in the presence of S9, 7,12-dimethylbenz[a]anthracene and aflatoxin B-1 responded without the MAS. Inhibition of cellular CYP3A4 or CYP1A/1B suppressed the aflatoxin B-1- and dimethylbenz[a]anthracene-mediated P53 response, respectively, indicating that HepG2 cells are capable of metabolizing these compounds in a CYP1A/B/3A4-dependent manner. In summary, our results indicate that P53 activation in HepG2 cells combined with a MAS can be used for the identification of new (pro)genotoxicants. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

引用

页码：272 / 281

页数：10

共 71 条

[1] Effect of metformin on clastogenic and biochemical changes induced by adriamycin in Swiss albino mice [J].

Aleisa, A. M. ;

Al-Rejaie, S. S. ;

Bakheet, S. A. ;

Al-Bekari, A. M. ;

Al-Shabanah, O. A. ;

Al-Majed, Abdulhakeem ;

Al-Yahya, Abdulaziz A. ;

Qureshi, S. .

MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 2007, 634 (1-2) :93-100

[2]

*ATCC, 2010, HEPG2 PROD DESCR

[3] Genotoxicity of several clinically used topoisomerase II inhibitors [J].

Boos, G ;

Stopper, H .

TOXICOLOGY LETTERS, 2000, 116 (1-2) :7-16

[4] An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons [J].

Brandon, EFA ;

Raap, CD ;

Meijerman, I ;

Beijnen, JH ;

Schellens, JHM .

TOXICOLOGY AND APPLIED PHARMACOLOGY, 2003, 189 (03) :233-246

[5] The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide [J].

Brantley-Finley, C ;

Lyle, CS ;

Du, LH ;

Goodwin, ME ;

Hall, T ;

Szwedo, D ;

Kaushal, GP ;

Chambers, TC .

BIOCHEMICAL PHARMACOLOGY, 2003, 66 (03) :459-469

[6] ABNORMAL STRUCTURE AND EXPRESSION OF P53 GENE IN HUMAN HEPATOCELLULAR-CARCINOMA [J].

BRESSAC, B ;

GALVIN, KM ;

LIANG, TJ ;

ISSELBACHER, KJ ;

WANDS, JR ;

OZTURK, M .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (05) :1973-1977

[7] ETHOXYPHENOXAZONES, PENTOXYPHENOXAZONES, AND BENZYLOXYPHENOXAZONES AND HOMOLOGS - A SERIES OF SUBSTRATES TO DISTINGUISH BETWEEN DIFFERENT INDUCED CYTOCHROMES-P-450 [J].

BURKE, MD ;

THOMPSON, S ;

ELCOMBE, CR ;

HALPERT, J ;

HAAPARANTA, T ;

MAYER, RT .

BIOCHEMICAL PHARMACOLOGY, 1985, 34 (18) :3337-3345

[8] CYP1B1 determines susceptibility to low doses of 7,12-dimethylbenz[a]anthracene-induced ovarian cancers in mice:: correlation of CYP1B1-mediated DNA adducts with carcinogenicity [J].

Buters, J ;

Quintanilla-Martinez, L ;

Schober, W ;

Soballa, VJ ;

Hintermair, J ;

Wolff, T ;

Gonzalez, FJ ;

Greim, H .

CARCINOGENESIS, 2003, 24 (02) :327-334

[9] Inhibiting the p53-MDM2 interaction:: An important target for cancer therapy [J].

Chène, P .

NATURE REVIEWS CANCER, 2003, 3 (02) :102-109

[10] CHARACTERIZATION OF 7,12-DIMETHYLBENZ[ALPHA]ANTHRACENE-ADENINE NUCLEOSIDE ADDUCTS [J].

CHENG, SC ;

PRAKASH, AS ;

PIGOTT, MA ;

HILTON, BD ;

ROMAN, JM ;

LEE, H ;

HARVEY, RG ;

DIPPLE, A .

CHEMICAL RESEARCH IN TOXICOLOGY, 1988, 1 (04) :216-221

← 1 2 3 4 5 6 7 8 →